A Study on the Prevalence of Clinically Useful Mutations in Solid Tumor Characterized by Next Generation Sequencing Methods on Liquid Biopsy Analysis (POPCORN)

Recruiting

• Conditions: Breast Cancer; Melanoma; Advanced Solid Tumor; Pancreatic Cancer; Bile Duct Cancer; Ovarian Cancer; Cervical Cancer; Locally Advanced Solid Tumor; Colon Rectal Cancer; Gastric Cancer

• Registration Number: NCT06028724
• Lead Sponsor: Centro di Riferimento Oncologico - Aviano

Brief Summary

The implementation of liquid biopsy in clinical practice has been favored by the rapid development of genome sequencing techniques designed to analyze mutations in ctDNA. Among these, the Next generation sequencing (NGS) is a technique that consists in sequencing several genomes in a short time span, collecting information about a wider range of genomic alterations, using small quantities of genetic material. It is used to identify potential circulating dynamic biomarkers of treatment sensitivity or resistance in a real word multi-pathology evaluation. In this way, defining the mutational status of clinical relevance genes in real world, as a predictive biomarker to identify those patients most likely to benefit from target therapy, offers the potential to optimize access to further therapies. The aim of this study is to evaluate the real-world prevalence of clinically useful mutations in patients who are receiving therapy for advanced and locally advanced solid tumor through liquid biopsy.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-05-26
• Status Verified: 2023-08
• Study First Submitted: 2023-08-03
• Study First Submitted QC: 2023-09-07
• Study First Posted: 2023-09-08
• Last Update Submitted: 2023-09-08
• Last Update Posted: 2023-09-13
• Primary Completion: 2030-05-31
• Study Completion: 2030-05-31

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 782

Inclusion Criteria

Patients eligible for inclusion in this study have to meet all of the following criteria:

• Patients, 18 years of age or older
• Competent and able to comprehend, sign and date an Ethics Committee (EC) approved Informed Consent Form (ICF) before performance of any study-specific procedures or tests
• Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
• Histologically proven diagnosis solid tumor
• Diagnosis of advanced or locally advanced disease
• Patients candidated to receive standard therapy in the following line:
• first, second or third-line therapy for colon-rectal cancer in IV stage
• first or second-line therapy for gastric cancer in IV stage
• primary intent or first-line therapy for pancreatic cancer
• first-line therapy for bile duct cancer
• first or second-line therapy for hepatocarcinoma
• first, second, third, fourth or fifth-line therapy for breast cancer in IV stage
• chemotherapy for ovarian cancer in advanced stage (FIGO III-IV) and at the time of first relapse
• first or second-line therapy for endometrial cancer in advanced stage (FIGO III-IV)
• first or second-line therapy for advanced or locally advanced cervical cancer
• therapy for locally advanced or first line therapy for metastatic vulva cancer
• first, second or third-line therapy for melanoma (third-line therapy only in BRAF-mutated melanoma)

Exclusion Criteria

• Diagnosis of any secondary malignancy within the last 3 years, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix.
• Patients unable or unwilling to undergo as per protocol assessments at the four planned timepoints

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Real world prevalence of clinically useful mutations in solid tumors	at the beginning of treatment	Real world prevalence of clinically useful mutations in solid tumors, defined as the proportion of patients with the detection of clinically useful mutations through ctDNA NGS, at the beginning of systemic therapies defined as per inclusion criteria for advanced disease.

Secondary Outcome Measures

Name	Time	Method
To identify emerging gene alterations associated with Progression Free Survival	from study enrollment until progression or death for any cause, up to 7 years	To identify emerging gene alterations associated with Progression Free Survival (PFS) defined as the time from study enrollment until progression or death for any cause, whichever comes first
To evaluate the association between somatic genetic alterations and pattern of metastasis	up to 7 years	Frequency of somatic genetic alterations in subgroups of patients with metastasis
To evaluate the association between somatic genetic alterations and the histopathological features of the tumor	up to 7 years	Frequency of somatic genetic alterations in subgroups of patients with different histopathological tumor characteristics
To evaluate the association between somatic genetic alterations and the clinical characteristic of the enrolled patients	up to 7 years	Frequency of somatic genetic alterations in subgroups of patients with different clinical characteristics
To identify emerging gene alterations associated with Overall Survival	from study enrollment until death for any cause, up to 7 years	To identify emerging gene alterations associated with Overall Survival, defined as the time from study enrollment until death for any cause
To describe changes in ctDNA associated biomarkers during treatment	up to 7 years	Difference in frequency of patients with ctDNA associated biomarkers at different time point during treatment (at baseline, at start of cycle 2, at first radiological evaluation, at relapse or end of follow-up)

Trial Locations

Locations (1)

IRCCS, Centro di Riferimento Oncologico (CRO) di Aviano; 🇮🇹 Aviano, Pordonone, Italy